One year of recombinant human growth hormone treatment in adults with Prader-Willi syndrome improves body composition, motor skills and brain functional activity in the cerebellum
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Casamitjana, Laia
- dc.contributor.author Blanco Hinojo, Laura, 1981-
- dc.contributor.author Giménez Palop, Olga
- dc.contributor.author Pujol, Jesús
- dc.contributor.author Martínez-Vilavella, Gerard
- dc.contributor.author Esteba-Castillo, Susanna
- dc.contributor.author Pareja, Rocío
- dc.contributor.author Freijo, Valentín
- dc.contributor.author Vigil, Laura
- dc.contributor.author Deus, Joan
- dc.contributor.author Caixàs, Assumpta
- dc.date.accessioned 2022-09-30T05:51:16Z
- dc.date.available 2022-09-30T05:51:16Z
- dc.date.issued 2022
- dc.description.abstract We compared body composition, biochemical parameters, motor function, and brain neural activation in 27 adults with Prader-Willi syndrome and growth-hormone deficiency versus age-and sex-matched controls and baseline versus posttreatment values of these parameters after one year of recombinant human growth hormone (rhGH) treatment. To study body composition, we analyzed percentage of fat mass, percentage of lean mass, and muscle-mass surrogate variables from dual X-ray absorptiometry. Biochemical parameters analyzed included IGF-I, glucose metabolism, and myokines (myostatin, irisin, and IL6). To explore muscle function, we used dynamometer-measured handgrip strength, the Timed Up and Go (TUG) test, and the Berg Balance Scale (BBS). To study brain activation, we acquired functional magnetic resonance images during three motor tasks of varying complexity. After one year of treatment, we observed an increase in lean mass and its surrogates, a decrease in fat mass, improvements in TUG test and BBS scores, and increased neural activation in certain cerebellar areas. The treatment did not significantly worsen glucose metabolism, and no side-effects were reported. Our findings support the benefits of rhGH treatment in adults with Prader-Willi syndrome and growth-hormone deficiency on body composition and suggest that it may also improve balance and brain neural activation.
- dc.format.mimetype application/pdf
- dc.identifier.citation Casamitjana L, Blanco-Hinojo L, Giménez-Palop O, Pujol J, Martínez-Vilavella G, Esteba-Castillo S, Pareja R, Freijo V, Vigil L, Deus J, Caixàs A. One year of recombinant human growth hormone treatment in adults with Prader-Willi syndrome improves body composition, motor skills and brain functional activity in the cerebellum. J Clin Med. 2022 Mar 25;11(7):1831. DOI: 10.3390/jcm11071831
- dc.identifier.doi http://dx.doi.org/10.3390/jcm11071831
- dc.identifier.issn 2077-0383
- dc.identifier.uri http://hdl.handle.net/10230/54230
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof J Clin Med. 2022 Mar 25;11(7):1831
- dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri https://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Prader–Willi syndrome
- dc.subject.keyword fMRI
- dc.subject.keyword Growth hormone
- dc.subject.keyword Hypotonia
- dc.subject.keyword Motor function
- dc.subject.keyword Myokines
- dc.title One year of recombinant human growth hormone treatment in adults with Prader-Willi syndrome improves body composition, motor skills and brain functional activity in the cerebellum
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion